Novel Genes AssociatedwithMalignantMelanoma but not BenignMelanocytic Lesions
D. Talantov,A. Mazumder,Jack Yu,T. Briggs,Yuqiu Jiang,J. Backus,D. Atkins,Yixin Wang
Abstract:Purpose: Cutaneous melanoma is a common, aggressive cancer with increasing incidence.The identificationofmelanoma-specific deregulated genes could providemolecularmarkers for lymph node staging assays and further insight into melanoma tumorigenesis. Experimental Design:Total RNA isolated from45primarymelanoma,18 benign skinnevi, and 7 normal skin tissue specimens were analyzed on an Affymetrix Hu133A microarray containing 22,000 probe sets. Results:Hierarchical clustering revealed a distinct separation of the melanoma samples from the benign andnormal specimens. Novel genes associatedwithmalignantmelanomawere identified. Differential gene expression of twomelanoma-specific genes, PLAB and L1CAM, were tested by a one-step quantitative reverse transcription-PCR assay on primary malignant melanoma, benign nevi, and normal skin samples, as well as on malignant melanoma lymph node metastasis and melanoma-free lymph nodes.The performance of the markers was compared with conventional melanomamarkers such as tyrosinase, gp100, andMART1. Conclusion:Our study systematically identifiednovelmelanoma-specific genes and showed the feasibility of using a combination of PLAB and L1CAM in a reverse transcription-PCR assay to differentiate clinically relevant samples containing benign ormalignant melanocytes. Cutaneous malignant melanoma is a serious healthcare problem with >55,100 new cases anticipated in 2004 in the U.S., with a mortality rate of about 14.5% (1). The incidence of melanoma continues to increase faster than that of any other malignancy (2). Although the prognosis for early local melanoma is favorable with 5-year overall survival of >90%, regional lymph node involvement decreases the overall survival rate by 10% to 46% (3). Therefore, regional lymph node status becomes the most significant prognostic factor for a melanoma patient’s survival. Introduction of the sentinel lymph nodes technique (4) has increased the sensitivity of melanoma micrometastasis detection compared to H&E staining alone (5, 6). Nevertheless, even with enhanced by immunohistochemistry, histologic analysis is limited by the ability of light microscopy to recognize the tumor cells. Reverse transcriptionPCR (RT-PCR) analysis has recently been proposed for a more sensitive detection of melanoma cells in lymph nodes. Many studies, when using well-characterized melanocyte-specific markers, such as tyrosinase and MART-1, have shown the presence of these gene transcripts in the lymph node, which were negative when using routine histologic and immunohistochemical methods (7, 8). However, these genes are not specific to tumor cells and cannot be used to discriminate between benign and malignant tissue. In fact, they cause falsepositive results in the presence of benign capsular nevi (9–11). Considering that benign nevi are not rare events in the melanoma sentinel lymph nodes, the current RT-PCR assays are not clinically useful for the diagnostics of melanoma micrometastasis. Hoon et al. proposed a multimarker panel, including cancer-specific markers, for RT-PCR assay in order to increase assay specificity (11). The identification of novel melanoma-specific markers remains one of the key objectives in melanoma research. High-density microarrays have been applied to simultaneously monitor the expression of thousands of genes in biological samples. Studies have resulted in the identification of genes differentially expressed in benign and malignant lesions (12), as well as genes that might be of prognostic value (13). In their pioneering work, Bittner et al. (14) did gene expression profiling of malignant melanoma, using a microarray containing probes for 8,150 cDNAs. These researchers identified several genes that might be associated with aggressive tumor behavior. In the recent work of Hoek et al. (15), comparison of gene expression profiles of a few melanoma and normal melanocyte cell lines led to the identification of differentially expressed genes and pathways modulated in melanoma. In this study, we report the gene expression profiling of an extensive set of clinically relevant tissue samples. Forty-five primary malignant melanomas, 18 Human Cancer Biology Authors’Affiliation: Veridex, LLC, a Johnson & Johnson Company, San Diego, California Received 3/28/05; revised 5/31/05; accepted 7/14/05. The costs of publication of this article were defrayed in part by the payment of page charges.This article must therefore be hereby marked advertisement in accordance with18 U.S.C. Section1734 solely to indicate this fact. Note: Supplementary data for this article are available at Clinical Cancer Research (http://clincancerres.aacrjournals.org/). Requests for reprints:YixinWang,Veridex, LLC, aJohnson & Johnson Company, 3210 Merryfield Row, San Diego, CA 92121. Phone: 858-784-3295; Fax: 858450-2070; E-mail: ywang44@ vrxus.jnj.com. F2005 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-05-0683 www.aacrjournals.org Clin Cancer Res 2005;11(20) October15, 2005 7234 Research. on May 28, 2017. © 2005 American Association for Cancer clincancerres.aacrjournals.org Downloaded from benign skin nevi, and 7 normal skin tissues were hybridized on an Affymetrix Hu133A microarray (Santa Clara, CA) containing 22,000 probe sets. Differentially expressed genes in malignant melanoma, as compared with benign tissue, were identified. A one-step quantitative RT-PCR assay was used to test a combination of two melanoma-specific genes, PLAB and L1CAM, in a panel of clinically relevant samples that included primary malignant melanoma, benign nevi, melanoma lymph node metastasis and melanoma-free lymph node samples. Materials andMethods Tissue samples. Fresh-frozen malignant melanoma, benign skin nevi, normal skin, melanoma lymph node metastasis, and melanomafree lymph node samples were obtained from Genomics Collaborative, Inc. (Cambridge, MA), Asterand (Detroit, MI), Clinomics (Pittsfield, MA), Proteogenex (Los Angeles, CA), Ardais (Lexington, MA), and Impath (Westborough, MA). All tissue vendors declared that tissue specimens used in the presented study were collected according to an Institutional Review Board–approved protocol of corresponding hospitals and principles of bioethics. Patient demographics and pathology information were also collected. The histopathologic features of each sample were reviewed to confirm diagnosis and to estimate sample preservation and tumor content. Melanoma and benign nevi primary tissues chosen for microarray analysis had melanocyte content of >50% with no mixed histology. Melanomapositive lymph nodes were collected from malignant melanoma patients and the diagnosis of melanoma was confirmed by H&E in combination with immunohistochemistry (S100 and HMB45). Melanoma-free lymph nodes derived from patients that did not have melanoma in their clinical history and absence of melanoma was confirmed by H&E and immunohistochemistry using antibodies for S100 and HMB45. RNA isolation and microarray hybridization. Qiagen RNeasy mini kit (Qiagen Inc., Valencia, CA) was used with a modified protocol to minimize the residue melanin in the RNA sample. For melanocytecontaining tissues, four replicate tissue samples derived from individual patients, each weighed f5 mg, were used and processed separately. Tissue samples were homogenized in 1.0 mL RLT buffer (Qiagen) containing 10 AL of h-mercaptoethanol (Sigma Chemical Co., St. Louis, MO) by a mechanical homogenizer (UltraTurrex T8, IKA-Werke, Staufen, Germany). Following homogenization, samples were loaded on Qiagen RNeasy columns and followed by centrifugation. After discarding the flow-through, 700 mL of RW1 buffer was added. The column was kept at room temperature for 5 minutes and then centrifuged; this step was repeated thrice. Then we followed the standard Qiagen RNeasy mini kit protocol. To remove RNA from the silica gel membrane, a two-step elution was done. The total RNA derived from the same individual patient tissue was pooled and used for further analysis. Standard Trizol protocol was used for RNA isolation from tissues that do not contain a significant proportion of melanocytes. Tissue was homogenized in Trizol reagent (Invitrogen, Carlsbad, CA). After centrifugation, the top liquid phase was collected and total RNA was precipitated with isopropyl alcohol at 20jC. RNA pellets were washed with 75% ethanol, resolved in water and stored at 80jC until use. The RNA quality was examined with an Agilent 2100 Bioanalyzer RNA 6000 Nano Assay (Agilent Technologies, Palo Alto, CA). Labeled cRNA was prepared and hybridized with the high-density oligonucleotide array Hu133A Gene Chip (Affymetrix) containing a total of 22,000 probe sets according to standard manufacturer protocols. Arrays were scanned using Affymetrix protocols and scanners. For subsequent analysis, each probe set was considered as a separate gene. Expression values for each gene were calculated by using Affymetrix Gene Chip analysis software MAS 5.0. Arrays that met three quality control standards were used: ‘‘present’’ call was >35%, scale factor was <12 when scaled to a target intensity of 600, and background level was <150. A lower than usual percentage of ‘‘present’’ calls cutoff was chosen because it is difficult to isolate undegraded RNA from the skin samples (16), resulting in lower overall gene expression levels. Data analysis. Gene expression data were filtered to include only genes that are called ‘‘present’’ in two or more samples. This filter was used to remove genes that did not change expression in the samples. Of the 22,000 genes presented on the array, 15,795 passed this filter and were used for hierarchical clustering. Prior to clustering, each gene expression signal was divided by the median expression in all the samples in the data set. This standardization step minimized the effect of the magnitude of gene expression and grouped together genes with similar expression patterns in the clustering analysis. Average